

CHIRON CORP  
Form 8-K  
July 20, 2005

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **July 20, 2005**

**Chiron Corporation**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other  
jurisdiction of  
incorporation)

**0-12798**  
(Commission  
File Number)

**94-2754624**  
(IRS Employer  
Identification No.)

**4560 Horton Street, Emeryville, CA**  
(Address of principal executive offices)

**94608**  
(Zip Code)

Registrant's telephone number, including area code **(510) 655-8730**

**N/A**

(Former name or former address, if changed since last report)

Edgar Filing: CHIRON CORP - Form 8-K

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
  - o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
  - o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
  - o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Items 2.02 and 7.01. Results of Operations and Financial Condition and Regulation FD Disclosure**

On July 20, 2005, Chiron Corporation (the Company) issued a press release announcing that the Company will not be able to supply any BEGRIVAC influenza virus vaccine doses to non-U.S. markets during the 2005-2006 influenza season. A copy of the Company's press release is attached as Exhibit 99.1 to this report. As a result, the Company expects to incur an inventory write-off of approximately \$15 million for the fiscal quarter ended June 30, 2005.

The information in this Current Report on Form 8-K, including the exhibit attached hereto, is furnished pursuant to Items 2.02 and 7.01 and shall not be deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section.

**Item 9.01. Financial Statements and Exhibits.**

(a) Financial statements of businesses acquired.

Not applicable.

(b) Pro forma financial information.

Not applicable.

(c) Exhibits.

Not applicable.

<b>Exhibit Number</b>	<b>Description</b>
99.1	Press Release issued July 20, 2005.

# # #



**SIGNATURE**

**SIGNATURE**



Edgar Filing: CHIRON CORP - Form 8-K

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**CHIRON CORPORATION**  
(Registrant)







Edgar Filing: CHIRON CORP - Form 8-K

Date: July 20, 2005

By: /s/ Ursula B. Bartels  
Ursula B. Bartels

Vice President,



Secretary